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Abstract
Embryonic stem cell research has proved enormously controversial in the United States and in other
nations such as Germany, France, and Japan. For the most part, the controversy over stem cell research
has hinged on the morality of destroying human embryos to obtain stem cells to culture cell lines for
research purposes. Some think that an embryo is a human being from the moment of conception, with
full moral standing and rights. Others argue that whereas human embryos may have some moral
standing, their moral status does not preclude their destruction for a moral purpose such as clinical
research aimed at the treatment of severely disabling or fatal diseases.

Comments
Reprinted from Western Journal of Medicine, Volume 176, Issue 2, March 2002, pages 78-79.

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/bioethics_papers/42

Op-Ed
Cloning human embryos
Arthur L Caplan

Robert and Emanuel Hart
Professor and Director
Glenn McGee

Associate director for
education
Center for Bioethics
University of
Pennsylvania
Philadelphia, PA 19104
Correspondence to:
Dr Caplan

caplan@mail.med.
upenn.edu
Competing interests:

None declared
West J Med
2002;176:78-79

78 wjm Volume 176 March 2002

Embryonic stem cell research has proved enormously controversial in the United States and in other nations such as
Germany, France, and Japan. For the most part, the controversy over stem cell research has hinged on the morality
of destroying human embryos to obtain stem cells to culture cell lines for research purposes. Some think that an
embryo is a human being from the moment of conception, with full moral standing and rights. Others
argue that whereas human embryos may have some moral
standing, their moral status does not preclude their
destruction for a moral purpose such as clinical research
aimed at the treatment of severely disabling or fatal
diseases.
The ethical debate grew so heated in the United States
that it became the subject of President Bush’s first major
speech to the nation on August 9, 2001. He indicated that
he opposed the destruction of human embryos but that he
could support the spending of federal funds for research
using stem cell lines already in existence before the date of
his speech. He claimed that there were 64 such cell lines
available, although subsequently several government officials have been forced to admit that this number may be
significantly overestimated.1
As this controversy has evolved, another has been moving almost in tandem with it—the controversy over human cloning. Ever since the creation of Dolly the sheep
was announced in February 1997, various parties have
proclaimed their willingness to attempt human cloning.
This has led to a storm of protest from many quarters and
resulted in bans on human reproductive cloning in more
than two dozen nations and several states in the United
States. No federal funding is permitted for human cloning
in the United States, and the House of Representatives
enacted a bill in 2001 that prohibits all human cloning.2
These two highly contentious subjects crossed paths
when Advanced Cell Technology (ACT), a small biotech
company in Worcester, Massachusetts, claimed on November 27, 2001 to have created the first cloned human
embryo. On the final day of the Thanksgiving weekend,
the company blitzed newspapers and television networks
worldwide with faxes and phone calls to stake their claim
in cloning history. The company used Scientific American,
US News and World Report, and a new Internet journal as
its publication venues.3 Company president Michael West
explained to a startled world on NBC’s Meet the Press how
scientists at his company had cloned humans “to the embryonic stage.” They would thus be able to create stem
cells, for therapeutic purposes, from the DNA of patients
requiring therapy. This would solve the problem of im-

munologic rejection that occurs if stem cells from genetically different sources are used.
The publicity campaign was met with a tide of condemnation. Within hours of the Meet the Press broadcast,
the President of the United States, the Pope, several congressional leaders, various prominent religious figures,
many newspaper editorials, and a large number of politicians from all over the world condemned ACT’s work as
blatantly immoral. Within days, scientists in the United
States and other nations were raising serious questions
about what ACT had actually accomplished in its laboratories with respect to human cloning. Within a month,
many involved with bioethics and science policy were raising questions about why ACT had chosen to announce its
“breakthrough” in the manner that it had. The company
quickly withdrew its initial claims, stating 3 days after the
initial public relations blitz that they had not made embryos but a “ball of cells.”
The announcement of the creation of the first cloned
human embryo was a major setback for rational discussion
of the ethics of stem cell research and cloning. ACT did
not offer solid proof that it had either created a viable
human clone or cloned a human embryo. It did excise
DNA from adult cells donated by a paralyzed physician
employed at the company and transfer that DNA to human eggs from which the nuclei had been removed. The
eggs had been sold to ACT by a young woman for
$4,000. The newly constructed egg was activated so that it
began to develop like an ordinary embryo, using a proce-
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dure similar to that devised by Ian Wilmut and colleagues
to clone Dolly. But the mixture stopped developing at the
eight-cell stage, within just a matter of hours after it was
activated. Scientists around the world, including Wilmut
himself, argued that an announcement of three cell divisions hardly merited publication, much less a press release.
The announcement of the first cloned human embryo
wound up generating not only shock and surprise among
nonscientists but scorn and contempt among many mainstream scientists and a powerful backlash against the use of
cloning for the purposes of stem cell research.4
It is impossible to know why ACT acted as it did.
Perhaps the company’s leaders sought the fame that the
announcement of the first cloned human embryo would
bring. Perhaps they were eager to obtain financial support
for a relatively new start-up company. Perhaps they simply
did not think through the consequences of their announcement. In any event, what their actions reveal is just
how unacceptable it is to leave momentous decisions such
as these in private hands behind closed doors.
The decision to create the first human cloned embryo
should not have been announced in the manner that it
was. The sudden and unexpected announcement produced a policy panic.5 The ethical backlash against this
experiment shows that more responsible conduct on the
part of those working in embryonic stem cell research is
required. Not only was the announcement politically dangerous, but also it was unfair to those who are ill or disabled. It is cruel to suggest to patients and their families,
who are desperate for treatments for severely disabling and
lethal diseases, that cures will soon be forthcoming from
stem cell research involving human embryos or cloned
human embryos. The recent history of gene therapy shows
just how difficult the road is in traveling from basic biologic research to clinical success.
The President and Congress need to rethink what has
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gone on so far in embryonic stem cell research. To date,
public policy has hinged on the assumption that it is
wrong to create and destroy human embryos; that cloning
human embryos is immoral whatever the goal; and that if
this work is to proceed, it is best left to the private sector.
None of these assumptions has been adequately debated,
much less have any of them secured broad consensus
among scientists or the general public. It is time to rethink
the promise of embryonic stem cell research, the role that
the public and private sectors should play in such research,
who should own this emerging technology, and what the
consequences are of prohibiting the destruction of all human embryos. It is even time to try and resolve the questions of what exactly is a cloned human embryo—a potential person, simply a ball of cells, or something else?
Until and unless this is done, those who wait for cures and
those who wish to pursue them will be ill served by science, business, and politics.
Authors: Arthur L Caplan is the director of the Center for Bioethics at
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